Placebo, MK-6240, ABBV-916 clinical trials

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects with Early Alzheimer's Disease

This study is looking into a new medication for early Alzheimer's disease. Researchers want to see if it's safe and helps reduce certain changes in the brain that are linked to the condition. It's a key step in understanding potential new treatments.